-
公开(公告)号：US20230322924A1
公开(公告)日：2023-10-12
申请号：US18180225
申请日：2023-03-08
Applicant: Janssen Biotech, Inc.
Inventor： Francois Gaudet , Jill Giles-Komar , Bradley Heidrich , Chichi Huang , Colleen Kane , Ronan Mcdaid , Jennifer Nemeth-Seay
IPC: C07K16/28 , A61P35/00 , A61K39/395 , C07K16/30
CPC classification number: C07K16/2809 , A61P35/00 , A61K39/39541 , C07K16/28 , C07K16/2803 , C07K16/3069 , A61K2039/505
Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
-
公开(公告)号：US20240262921A1
公开(公告)日：2024-08-08
申请号：US18643356
申请日：2024-04-23
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo ATTAR , Rajkumar Ganesan , Francois Gaudet , Bradley J. Heidrich , Carmen Baca Jones , John Lee , Yingzhe Li , Sanjaya Singh , Sathya Venkataramani
CPC classification number: C07K16/2866 , A61K9/0019 , A61P35/00 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/74 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33
Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
-
公开(公告)号：US12012461B2
公开(公告)日：2024-06-18
申请号：US16412831
申请日：2019-05-15
Applicant: Janssen Biotech, Inc. , Stichting VUmc
Inventor： Homer Adams , Francois Gaudet , Niels Van de Donk , Kris Frerichs , Christie Verkleij
CPC classification number: C07K16/2896 , A61K45/06 , A61P35/00 , A61P35/02 , C07K16/2809 , C07K16/2878 , C07K16/30 , C07K16/468 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/71
Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
-
公开(公告)号：US20240101697A1
公开(公告)日：2024-03-28
申请号：US18208361
申请日：2023-06-12
Applicant: Janssen Biotech, Inc. , Stichting VUmc
Inventor： Homer Adams , Francois Gaudet , Niels Van de Donk , Kris Frerichs , Christie Verkleij
CPC classification number: C07K16/2896 , A61K45/06 , A61P35/00 , A61P35/02 , C07K16/2809 , C07K16/2878 , C07K16/30 , C07K16/468 , A61K2039/505 , C07K2317/21 , C07K2317/31
Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
-
公开(公告)号：US11884722B2
公开(公告)日：2024-01-30
申请号：US18157800
申请日：2023-01-20
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Francois Gaudet , Mark Tornetta , Alexey Teplyakov , Mark Mendonca , Suzanne Edavettal , Kodandaram Pillarisetti , Nathan Majewski , Yingzhe Li , Leopoldo L. Luistro, III , Diana Chin
IPC: A61K39/395 , C07K16/28 , A61K39/00
CPC classification number: C07K16/28 , A61K39/0011 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
-
Patent Agency Ranking
公开(公告)号：US11603405B2
公开(公告)日：2023-03-14
申请号：US16418082
申请日：2019-05-21
Applicant: Janssen Biotech, Inc.
Inventor： Francois Gaudet , Jill Giles-Komar , Bradley Heidrich , Chichi Huang , Colleen Kane , Ronan McDaid , Jennifer Nemeth-Seay
IPC: C07K16/28 , A61P35/00 , A61K39/395 , C07K16/30 , A61K39/00
Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.
-
7.发明申请Prostate Specific Membrane Antigen (PSMA) Bispecific Binding Agents and Uses Thereof 审中-公开前列腺特异性膜抗原（PSMA）双特异性结合剂及其用途公开(公告)号：US20160347840A1
公开(公告)日：2016-12-01
申请号：US15148371
申请日：2016-05-06
Applicant: Janssen Biotech, Inc.
Inventor： Glenn Anderson , Rosa Cardoso , Michael Diem , Francois Gaudet , Shalom Goldberg , Benjamin Harman , Linus Hyun , Steven Jacobs , Donna Klein , Yingzhe Li , Jinquan Luo , Ronan McDaid , Jill Mooney , Jennifer Nemeth-Seay , Karyn O'Neil , Steven Pomerantz , Galla Chandra Rao , Tracy Spinka-Doms , Alexey Teplyakov , Leopoldo Luistro , Sheng-Jiun Wu
IPC: C07K16/28 , C07K14/78 , A61K45/06 , C07K16/30 , A61K39/395
CPC classification number: C07K16/2809 , A61K45/06 , A61K47/6803 , A61K47/6869 , A61K49/0045 , A61K49/0058 , A61K2039/505 , C07K14/78 , C07K16/3069 , C07K2317/24 , C07K2317/31 , C07K2317/524 , C07K2317/53 , C07K2317/55 , C07K2317/70 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C12Y304/17021
Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
Abstract translation: 本文提供了分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段，其中FN3结构域特异性结合人前列腺特异性膜抗原（PSMA）和第二抗原结合位点免疫特异性结合CD3。 还描述了能够编码所提供的融合蛋白的融合蛋白和相关多核苷酸，以及表达所提供的融合蛋白的细胞。 此外，描述了使用所提供的分离的CD3×PSMA-双特异性抗原结合分子或其双特异性抗原结合片段的方法。
-
8.发明公开公开(公告)号：US20240343796A1
公开(公告)日：2024-10-17
申请号：US18528157
申请日：2023-12-04
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Francois Gaudet , Mark Tornetta , Alexey Teplyakov , Mark Mendonca , Suzanne Edavettal , Kodandaram Pillarisetti , Nathan Majewski , Yingzhe Li , Leopoldo L. Luistro, III , Diana Chin
CPC classification number: C07K16/28 , A61K39/0011 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
-
公开(公告)号：US20200231686A1
公开(公告)日：2020-07-23
申请号：US16743188
申请日：2020-01-15
Applicant: Janssen Biotech, Inc.
Inventor： Ricardo Attar , Rajkumar Ganesan , Francois Gaudet , Bradley J. Heidrich , Carmen Baca Jones , John Lee , Yingzhe Li , Sanjaya Singh , Sathya Venkataramani
Abstract: The present disclosure provides for chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor, G-protein coupled receptor family C group 5 member D (GPRC5D), and immunoresponsive cells comprising such CARs, for the treatment of cancer.
-
10.发明公开公开(公告)号：US20240301083A1
公开(公告)日：2024-09-12
申请号：US18657180
申请日：2024-05-07
Applicant: Janssen Biotech, Inc. , Stichting VUmc
Inventor： Homer Adams , Francois Gaudet , Niels Van de Donk , Kris Frerichs , Christie Verkleij
CPC classification number: C07K16/2896 , A61K45/06 , A61P35/00 , A61P35/02 , C07K16/2809 , C07K16/2878 , C07K16/30 , C07K16/468 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/71
Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.017 seconds)
